Loading
FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.
Transcriptional repressor. Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential. Plays an important role in the specification and differentiation of lung epithelium.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.67, somatic mutation 0.86). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Prostate Adenocarcinoma.
In plain words · FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.
FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.
Transcriptional repressor. Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential.
No product in this corpus aims at FOXP1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance) and a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA FOXP1: RNA low tissue specificity; high antibody staining in 24 normal tissues; highest cancer staining colorectal cancer (7 of 12 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Breast cancer (all types), Prostate cancer, Neuroendocrine tumours, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Oesophageal cancer and more); Open Targets associates it with 1 specific cancer type at or above 0.5 (skin cancer). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9H334; CIViC gene FOXP1; IntOGen FOXP1; Human Protein Atlas FOXP1 tissue; Open Targets ENSG00000114861 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Zhang Q.-H. et al, Genome Res, 2000, "Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells". Source.
Sources: HGNC HGNC:3823 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H334 (protein name, function text, keywords and locations (REST API)); CIViC gene FOXP1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000114861 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: gastric cancer 0.52, oesophageal cancer 0.51, prostate cancer 0.56, ovarian cancer 0.51, melanoma 0.64, neuroendocrine neoplasm 0.52 (GraphQL API, CC0)); IntOGen FOXP1 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional repressor. Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential. Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. Involved in regulation of cardiac muscle cell proliferation. Location: Nucleus (UniProt). Locus 3p13 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Cerebellum, Cervix, Endometrium, Esophagus, Fallopian tube, Heart muscle, Kidney.
Medium only: carcinoid, endometrial cancer, head and neck cancer, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FOXP1" OR ABSTRACT:"FOXP1" OR TITLE:"forkhead box P1" OR ABSTRACT:"forkhead box P1" OR TITLE:"Forkhead box protein P1" OR ABSTRACT:"Forkhead box protein P1" OR TITLE:"QRF1" OR ABSTRACT:"QRF1" OR TITLE:"12CC4" OR ABSTRACT:"12CC4" OR TITLE:"HSPC215" OR ABSTRACT:"HSPC215") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FOXP1, not a curated reading list.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), CIViC.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), IntOGen.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), CIViC.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), CIViC.
Shares Biliary tract cancer (all types), CIViC, IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares Biliary tract cancer (all types), Oesophageal cancer, CIViC, IntOGen.
Shares Biliary tract cancer (all types), Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Biliary tract cancer (all types), Skin cancer (all types), CIViC, IntOGen.